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SUMMARY
Objectives: to determine the age and sex specific incidence rates, presenting features, and visual
outcome ofidiopathic intracranial hypertension in Northern Ireland.
Methods: A case-note review ofall patients withidiopathicintracranialhypertension, diagnosed
at the Royal Victoria Hospital, Belfast between 1991 and 1995.
Results: Forty-two patients were identified corresponding to an average annual incidence rate
per 100,000 persons of 0.5 for the total and 0.9 for the female population. The commonest
presenting symptoms were headache (84%), transient visual obscurations (61%) and sustained
visual loss (34%). Impaired Snellen visual acuity and visual field loss were documented in 21%
and 62% of patients respectively at presentation, and in 24% and 39% at last follow-up. One
patient suffered deterioration in visual functioning sufficient to interfere with normal daily
activities. Conclusions: The age and sex specific incidence rates ofIIH in Northern Ireland are
lower than have been reported in previous population-based series. Disabling visual loss occurs
in a small number ofpatients despite all interventions.
INTRODUCTION
Idiopathic intracranial hypertension (IIH) is a
conditionofunknownaetiologycharacterizedby
symptoms and signs of increased intracranial
pressure in the absence of an intracranial lesion
orhydrocephalus. Allneuroscienceunitsmanage
IIH, yet information on epidemiology is very
limitedandisbasedonstudiesthathaveinvolved
either small numbers ofpatients or shortperiods
offollow-up.1-3FiguresforEuropeanpopulations
are unknown and some reports have suggested
that IIH is less common in Europe.4'5
Visualloss isthemostimportantcomplicationof
IIH. Previous studies have suggestedthat96% of
patients have visual abnormalities at sometime,6
andupto 10%developbilateralblindness.7There
are no controlled trials of treatments in this
condition,anddespitealltherapeuticinterventions
some patients develop progressive blindness.
The aims ofour study were: (1) to determine the
population-based incidence rates of IIH in
Northern Ireland, over a five year period (1991-
1995), (2) to provide clinical details of cases of
IIH diagnosed in our locality over this period,
and (3) to determine the frequency of visual
complications in our patients.
CASES AND METHODS
Caseswereidentifiedbyacomputersearchofthe
medical records for all patients treated at the
Royal VictoriaHospital (RVH), Belfastbetween
the 1st of January 1991 and 31st of December
1995 for whom the following diagnoses were
made;pseudotumourcerebri,benignintracranial
hypertension or IIH. The RVH is a university
teachinghospital,andhousestheonlydepartments
of neurology and neurosurgery and the main
departmentofophthalmologythatserveNorthern
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Ireland (Population 1.64 million). All patients
with IIH would be expected to be seen in this
hospital atsome stage. Inclusioninthestudywas
based on the Modified Dandy Criteria for IIH
(Table 1). To be considered, the diagnosis ofIIH
shouldhavebeenmadebetween 1stJanuary 1991
and the 31st ofDecember 1995 and residency in
Northern Ireland had to be established at least 1
year before diagnosis.
TABLE I
Modified Dandy Criteriafor the diagnosis of
idiopathic intracranial hypertension.8
1. Signsandsymptomsofincreasedintracranial
pressure.
2. Awake and alert patient,
3. No abnormal neurological findings except
papilloedema or a sixth nerve palsy.
4. Normal CT/MRI except for empty sella
syndrome or small ventricles.
5. DocumentedincreasedCSFopeningpressure
(>200 mm of water in non-obese and >250
mm of water in obese patient), with normal
CSF composition.
6. No other known cause ofraised intracranial
pressure.
Table II
Age and sex specific average annual incidence rates ofidiopathic intracranial hypertension per
100,000population in Northern Ireland, 1991 to 1995.
Females Males Total
Age Group,
years No. Rate No. Rate No. Rate
0-14 2 0.20 1 0.10 3 0.10
15-24 12 1.98 0 0.00 12 0.96
24-35 10 1.56 2 0.32 12 0.93
35-44 7 1.33 1 0.19 8 0.77
45+ 5 0.35 2 0.16 7 0.26
All age groups 36 0.86 6 0.15 42 0.51
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Age and sex specific incidence rates were
calculated by dividing the number of incident
cases by the proper denominator, gained from
censusdataforNorthern Ireland 1993. Datawere
independently collected from the case-notes by
two of the authors (JC + DM). The follow-up
period was to the 31st May 1996. Variables
collected were symptoms, and examination
findings, recorded at presentation and on each
visit.
RESULTS
Forty-two cases, with a mean age of 29 years at
diagnosis, were identified in the five-year study
period. Average annual incidence rates per
100,000personsforIIHbyageandsexareshown
intableII.Theaverageannualincidenceratesper
100,000 were 0.6 for the total and 0.9 for the
female population. The female-to-male ratio of
incidence rates was 5.7:1.0.
Symptoms(TableIII)Durationofsymptomsprior
to diagnosis varied from one to 208 weeks.
Headache was the presenting symptom in 32
cases and occurred daily in almost two-thirds.
Transient visual obscurations (TVOs) were
reportedby five ofthe six cases thatdidnothave
headache. Halfreported weight gain in the year
before diagnosis.
Eleven (26%) patients had magnetic resonance
(MR) imaging of brain with MR venography.
These were reported as normal for all cases.Idiopathic intracranial hypertension in Northern Ireland 33
TABLE III
Presenting symptoms
Symptom %
Headache 84
Transient visual obscurations 61
Sustained visual loss 34
Scintillations 18
Diplopia 11
Intracranial noises 8
Retrobulbar pain 5
Deafness 3
Weight gain 50
OphthalmologicalExamination Allpatientshad
optic disc swelling at presentation (Figure 1). In
eleven cases it was mild and in 21 moderate to
severe. Corrected Snellen visual acuity at
presentation was worse than 6/9 in at least one
eyeineight(21%)patients. Anabnormalityother
than enlargement ofthe blind spot was recorded
in 18 (62%) of the 29 who had perimetric
assessment of visual fields performed at
presentation. Thecommonestfieldabnormalities
noted were generalized constriction and infero-
nasal field defects (Figure 2).
Sixteen (42%) cases hadpersistent disc swelling
(tenmild,sixchronic)atlastfollow-up.Corrected
Snellen visual acuity was worse than 6/9 in at
least one eye in nine (24%) cases. Four ofthese
nine were cases whose visual acuity had been
normalatpresentation. Nonehaddeteriorationof
visual acuity sufficient to interfere with normal
daily activities. Seven (39%) ofthe 18 cases who
had visual field loss documented at presentation
had complete resolution of their defects. One
case had a worsening of field loss with marked
fieldconstrictiontowithin20degreesoffixation,
which interfered with activities of daily living.
The rest maintained persistent mild defects that
did not interfere with visual functioning.
Patients were treated with acetazolamide or
diuretics initially. Analgesic preparations taken
on aregularbasis by almostthree-quarters ofthe
patients were never effective at relieving
headache. Over half also had repeated lumbar
punctures. Weight loss was documented in eight
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Fig 1. Confocal laser tomogram of right eye of patient
showing significant disc swelling.
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of the 21 patients reporting significant weight
gain priorto symptom onset. This was sustained
infour, withthreehaving sustained symptomatic
improvementandreducedCSFopeningpressure.
Seven cases (18%) had a theco-peritoneal shunt
inserted. Optic nerve sheathfenestration was not
performed in any of the cases. Symptomatic
improvement occurred in all patients who had a
shunting procedure, which was maintained for a
meanof16months. Allpatientswhohadsurgical
managementdevelopedpost-operativeproblems,
including a return of symptoms of raised
intracranial pressure in six patients; one ofthese
patients also had a shunt infection. The other
patient developed chronic headache due to
persistently low cerebrospinal fluid pressure.
Further surgery, amounting to 15 additional
procedures, was necessary in four of these six
patients.
DISCUSSION
The average annual incidence rates of
symptomaticIIHinNorthernIrelandper 100,000
persons at0.5 forthe totalpopulation and0.9 for
females arelowerthanthosereportedinthethree
previously conducted population based studies
evaluating the incidence of this condition.1-3 In
these studies the incidences per 100,000 ranged
from0.9 to 1.7 forthe totalpopulation and 1.6 to
3.6 for females. Whether our results are due to
incomplete ascertainmentorthattheincidenceof
IIHis lowerinourlocality, dueto suchfactors as
thehigherfrequencyofobesityinthepopulations
previously studied, is unknown. Patients with
papilloedema and headache without tumour will
be referred to our single neuroscience centre;
diagnosis is precise and our population
denominator is stable. Thus we feel that the
observed rates are representative of the true
incidence rates of symptomatic IIH in Northern
Ireland.
Headache was less oftenthepresenting symptom
in our cases. Most of those who did not have
headache had TVOs. TVOs without headache
have been documented in IIH9 but never as
frequently as in our series. This highlights the
importanceofestablishingwhetherpapilloedema
and raised intracranial pressure are present in
patients with TVOs.
Visual acuity and visual fields were impaired in
a substantial number of patients at presentation
reflecting the delay between symptom onset and
diagnosis. Visual loss severe enough to interfere
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with activities of daily living was however
uncommon at any stage in our cases. In addition
the abnormalities found on testing visual
functioning often improved. Our results are in
keepingwiththoseofthepopulation-basedseries
from Rochester, Minnesota3 where nine patients
identifiedovera 15yearperiodfromapopulation
of70,000 were followed up for a median period
of2.7 years. Outof 18 eyes only three developed
visualimpairment. This was mildin allcases and
didnotinterferewitheverydayvisualfunctioning.
Such findings are at odds with the commonly
heldbeliefthatdisablingvisual loss is afrequent
result of IIH,6 and might be explained by the
relatively shortfollow-upperiodofourcasesand
those from Rochester. However, some of the
differencecouldalsobeaccountedforbyselection
bias in non-population-based studies with more
severely affected cases being studied.
Efficacy is claimed for medical treatments used
in IIH.6,10-14 There are however no controlled
trials of any of them and patients are therefore
managed according to personal or local
preferences. This is also the case for the surgical
procedures used. There is no doubt that surgical
intervention has saved vision in some patients
with IIH'5-'7 but the effectiveness of either
shunting procedures or optic nerve sheath
fenestration have never been studied in a
controlled way, and it is unclear when surgical
intervention shouldbeundertaken. Bothtypes of
procedure are also not infrequently associated
with post-operative complications;'8-22 some
patients may therefore be having an unnecessary
interventionwithattendantsignificantmorbidity.
In conclusion, we found that the age and sex
specific incidence rates of IIH are lower in
Northern Ireland than in previous population-
based studies and that visual loss sufficient to
interfere with normal activities was uncommon.
In keeping with the results from Rochester,
Minnesota, this raises the possibility that the
prognosisforvisioninIIHisbetterthanpreviously
suggested from the results of non-population
based series.
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